Navigation Links
NeurogesX Reports First Quarter 2011 Results
Date:4/29/2011

se initiatives allowed us to moderate planned spending growth and as a result, we have reduced our planned operating expenses for 2011 by approximately 14% from prior guidance.  Our 2011 operating expenses are now expected to be in the range of $50 million to $53 million.  Our primary focus remains on ensuring the continued adoption of Qutenza, recognizing the longer term nature of the investments necessary for success.  Other key activities include submission of a supplemental NDA for Qutenza for the management of neuropathic pain associated with HIV-associated neuropathy (HIV-AN) as well as advancing the clinical development of NGX-1998, our topical liquid formulation containing a high concentration capsaicin.  With our reduced expenses and continued focus on our key operational initiatives, we continue to pursue opportunities to increase our capital."  

Investor DayNeurogesX will host an investor day today from 8:15 am - 11:00 am EDT at The New York Palace Hotel in New York.  As part of the presentation, management will review results for the first quarter ended March 31, 2011.  The Company will provide an update on the US launch of the Qutenza® (capsaicin) 8% patch and on the development of NGX-1998. The Investor Day will be webcast live and archived for 30 days on the investor relations section of the NeurogesX website at www.neurogesx.com.

About NeurogesX, Inc.NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
2. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
3. NeurogesX to Provide Qutenza® Launch Update
4. NeurogesX to Present at Two February Investor Conferences
5. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
6. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
7. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
8. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
9. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
10. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
11. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
(Date:4/17/2014)... find a colored ribbon representing a disease. A pink ribbon ... ribbon does one think of with lung cancer?, Although white ... from the disease, black may be the only one they ... cancer patients, primarily smokers between the ages of 51 to ... often felt by these patients, the emotional toll it can ...
(Date:4/17/2014)... A new study has found that India,s shocking rates ... debt-ridden farmers who are clinging to tiny smallholdings ... ,cash crops, such as cotton and coffee, that are ... supports a range of previous case studies that point ... sector following the ,liberalisation, of the nation,s economy during ...
(Date:4/17/2014)... anti-malarial treatment that lost its status as the leading ... new lease of life, with new research indicating it ... could revive the use of the cheap anti-malarial drug ... claims the lives of more than half a million ... that causes malaria has developed resistance to chloroquine, but ...
(Date:4/16/2014)... HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. ... Phase 1 study of CDX-1401 in solid tumors, including ... Translational Medicine (Vol 6 Issue 232). The data ... of clinical benefit in patients with very advanced cancers ...
Breaking Medicine News(10 mins):Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... becoming apparent to the Government Health officials, albeit for the ... socks and gearing up to take stock of multi-drug resistant ... a public health initiative , developed by the World Health ... in Maharashtra and Gujarat. 100 MDR-TB cases are envisaged in ...
... at The University of Texas M. D. Anderson Cancer ... prostate cancer patients who are eligible for watchful // ... ,"With the advent of the PSA test, we ... no evidence that early detection means longer survival. Because ...
... recent progress in echocardiography providing doctors with improved imaging ... a // probe into the esophagus, which emits radio ... in enabling a motion picture of the heart, far ... images are capable of offering various options to doctors ...
... women who present to the sex clinic only report ... some women, may present with just the opposite complaints//. ... suffering from the so-called persistent sexual arousal syndrome (PSAS) ... ,Currently, very little is understood about this rare syndrome ...
... you badly in need of blood or are you inclined in ... it//? Either way, the solution for it is just a few ... simple yet amazingly useful venture in 2000. He works for Central ... of the venture too. ,If you're located in Kolkata ...
... is a mere 0.028 percent as compared to the national ... further, the military's top doctor said Thursday. ,"Contracting ... crime," Surgeon Vice Admiral Vijay K. Singh, director general of ... ,The national average of the incidence of HIV/AIDS ...
Cached Medicine News:Health News:New Network To Ease Blood donation In India 2Health News:Incidence Of HIV/AIDS In The Indian Armed Forces Negligible 2
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Medicine Products: